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Abstract Although nucleosides and nucleotides have a good
safety record for the treatment of hepatitis B, there have been
no systematic reviews on this topic. We searched Medline to
include studies of the oral antiviral agents for hepatitis B and
adverse events, with at least 48 weeks of follow-up from the
initiation of treatment with the drug. Important toxicities
include nephrotoxicity, myopathy, and resistance. It is often
difficult to ascertain whether an adverse effect is from the
study drug or the natural progression of the disease. Further
safety data are needed for the newer agents and for all agents
withregardtopatientswithdecompensatedliverdisease,renal
dysfunction, the elderly, children, and pregnant women.
Keywords Nucleosides.Nucleotides.Chronic hepatitis B
virus infection.Lamivudine.Entecavir.Telbivudine.
Adefovir dipivoxil.Tenofovir disoproxil fumarate
Introduction
Worldwide, 350 to 400 million people have chronic
hepatitis B virus infection (CHB). Among those chronically
infected, 20% to 40% develop cirrhosis, decompensated
liver disease, or hepatocellular carcinoma. Treatment of
CHB has evolved rapidly over the past decade as a result of
improvements in antiviral treatment. Initially, interferon-α
was the only available treatment, but it is effective in only
35% of patients and is poorly tolerated because of its
adverse effects. The nucleoside/nucleotide medications are
an important class of drugs that are changing the way CHB
is treated [1]. The aim of this article is to systematically
review the literature on side effects of currently approved
nucleoside and nucleotide drugs in the treatment of chronic
hepatitis B virus (HBV) infection in adults, focusing on
adverse events, serious adverse events, resistance, and
death.Thereare currentlythree nucleosidedrugs (lamivudine,
entecavir, and telbivudine) and two nucleotides (adefovir
dipivoxil, tenofovir disoproxil fumarate) approved in the
United States for the treatment of chronic HBV. Prolonged
treatment with these oral agents is recommended for selected
patients with HBV infection until disease remission or
serologic endpoints have been achieved. Indefinite treatment
is indicated for patients with HBVand advanced liver disease
or in some patients on chronic immunosuppressive therapy
[1, 2••, 3••].
The side effect profile for the five approved agents was
generally good during registration trials, but there have
been reports of serious adverse events including myopathy,
neuropathy, pancreatitis and renal impairment during post
marketing surveillance. As the oral agents have often been
administered to patients with HIV coinfection, it is
sometimes difficult to ascertain the role of HIVon reported
adverse events [1, 2••]. This important population cannot be
ignored, however. Every effort will be made in this article
to review the side-effects of these drugs in patients with
hepatitis B or for hepatitis B/HIV coinfection, and articles
reporting adverse events exclusively in patients with HIV
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DOI 10.1007/s11901-010-0039-1monoinfection will be excluded. Though there have been
important narrative reviews on adverse side-effects with
nucleos(t)ide drugs written previously, this article is the first
systematic review on the topic to our knowledge.
Established Side Effects of Nucleoside Analogues
Information on several established side effects of the
approved nucleoside and nucleotide drugs used for the
treatment of CHB are described in Table 1. Information
summarized in Table 1 includes year of approval, abbrevia-
tion, mechanism, clearance, dose, renal and dialysis-
adjusted dose, common side effects, and pregnancy category
[4••].
The five approved oral agents for CHB are analogues of
nucleosides or nucleotides that pharmacologically inhibit
the HBV polymerase in order to decrease viral replication
and serum HBV DNA levels. Some analogues have activity
against human mitochondrial DNA (mtDNA) polymerase
gamma and can lead to mitochondrial dysfunction. Mito-
chondrial toxicity can manifest clinically as one or more of
the following: myopathy, neuropathy, hepatic steatosis,
pancreatitis, macrocytosis, hyperlactemia, lactic acidosis,
and nephrotoxicity. All five approved agents carry a US
Food and Drug Administration black box warning of
potential mitochondrial toxicity [4••, 5]. Fialuridine is a
nucleoside analogue which caused lactic acidosis, hepatic
steatosis, pancreatitis, neuropathy, myopathy, and irreversible
liver failure. It irreversibly incorporated into human mito-
chondrial DNA, causing mitochondrial failure, and was
withdrawn from the market as a result [6].
Another important consideration is lactic acidosis, for
which all five approved oral agents carry a black box
warning. This black box warning originally derived from
the HIV literature, though cases have been reported with
nucleos(t)ide agents given at the lower doses recommended
for CHB. Recently, entecavir was found to cause lactic
acidosis in 5 of 16 patients (31%) in one study. All of the
patients who developed lactic acidosis had highly impaired
liver function, with a model for end-stage liver disease
(MELD) score ≥20. Lactic acidosis occurred between 4 and
240 days after treatment initiation and was lethal in one
patient, but resolved in the others with discontinuation of
entecavir. In patients with a MELD score less than 18, no
increased serum lactate concentrations were observed.
These data indicate that entecavir should be used with
caution in patients with impaired liver function [7]. All five
medications also carry a black box warning for posttreat-
ment flares of hepatitis. Adefovir dipivoxil carries a
warning for potential HIV resistance in HBV treated
patients with previously undiagnosed HIV [8–12].
Methods
We searched Medline for published articles up to October
2009 using a combination of search strings. The first
component of the search string was the antiviral drug. For
this, we searched each variation of the drug’s name,
including its trade names as text words, the name of the
drug searched as a MeSH term, and the substance name of
the drug. These variations were strung together with the
“OR” function in Medline. For example, with lamivudine,
the drug search was as follows: ("Lamivudine"[Text
Word] OR "3TC"[Text Word] OR "Epivir"[Text Word]
OR "Zeffix"[Text Word] OR "Heptovir"[Text Word] OR
"Epivir-HBV"[Text Word] OR "Lamivudine"[Mesh] OR
"lamivudine triphosphate "[Substance Name]). The second
component of our search string was the drug side effects.
For this component, we used the following string: ("com-
plicat*"[Text Word] OR "adverse effect*"[Text Word] OR
Table 1 FDA-approved oral antivirals for CHB
Lamivudine Adefovir Entecavir Telbivudine Tenofovir
Year of approval 1998 2002 2005 2006 2008













Clearance Renal Renal Renal Renal Renal
Dose 100 mg/d 10 mg/d 0.5 mg/d 600 mg/d 300 mg/d
Renal and dialysis-
adjusted dose













Pregnancy category C C C B B
CHB chronic hepatitis B virus infection, FDA US Food and Drug Administration, HBV hepatitis B virus
76 Curr Hepatitis Rep (2010) 9:75–90"adverse event*"[Text Word] OR "safe*"[Text Word]
OR "drug monitor*"[Text Word] OR "toxic*"[Text Word]
OR "poison*"[Text Word] OR etiol*[text word] OR aeitol*
[text word] OR causation[text word] OR causal*[text word]
OR "complications "[Subheading] OR "adverse effects
"[Subheading] OR "Safety"[Mesh] OR "Biomarkers, Phar-
macological"[Mesh] OR "Drug Toxicity"[Mesh] OR "Cau-
sality"[Mesh] OR "etiology "[Subheading] OR "prevention
and control "[Subheading] OR "chemically induced "[Sub-
heading]). The final component of our search string was
hepatitis B. We searched the following: ("Hepatitis
B"[Mesh] OR "Hepatitis B virus"[Mesh] OR "hepatitis
B"[Text Word]). Included under the broader category of
“Hepatitis B” in Medline is “Chronic Hepatitis B,”
obviating the need to explode the MeSH term. Because
MeSH subject headings are hierarchical, in order to retrieve
a term and its narrower terms, a subject heading must be
exploded. PubMed automatically explodes MeSH subject
headings to include all narrower terms unless “Do not
explode” is selected. Finally, the three components (drug,
side effect, and hepatitis B) were combined using the AND
function of Ovid Medline. We constructed a publication
type hedge in Medline to include the following types of
studies: randomized controlled trials, controlled clinical
trials, cohort studies, and case-control studies. We did not
restrict this review to randomized controlled trials due to
lack of randomized controlled trials devoted to reporting
harm. We chose our search strategy based on the Cochrane
Handbook’s Highly Sensitive Search Strategy for identifying
randomized trials in MEDLINE: sensitivity and precision
maximizing version with the addition of cohort studies and
case-control studies.
In the final review, we included all English-language
articles if they were 1) original research articles; 2) reported
side effects or adverse events of one of the nucleoside or
nucleotide drugs; 3) reported results for a population with
CHB (either with or without HIV); 4) involved only human
subjects; and 5) had at least 48 weeks of follow-up. If a
phase 3 trial was available, we included the phase 1 or 2
trial only if they contained data not reported in the phase 3
trial. If a trial was reported in two journals, we chose one of
the articles.
Results
Description of Study Characteristics
Table 2 provides the descriptive characteristics in terms of
author, country, study design, number of patients, partici-
pant characteristics, length of follow-up, outcomes
assessed, and primary purpose of the study for each article
included.
Lamivudine
Lamivudine (LAM) was the first oral nucleoside analogue
approved for the treatment of CHB, at a dose of 100 mg
daily. It is the negative enantiomer of 2′-3′ dideoxy-3′-
thiacytidine. Incorporation of 3TC-TP into growing DNA
results in premature chain termination inhibiting HBV
DNA synthesis. Lamivudine has been studied extensively
and has the well-documented adverse event of liver disease
flares due to the emergence of lamivudine-resistant HBV.
For the purpose of this review, lamivudine will be discussed
in narrative form as hundreds of studies fit the inclusion
criteria for this review. Lamivudine was approved for the
treatment of CHB in 1998 for adults and in 2001 for
children. It was thought to have a side effect profile similar
to placebo in registration trials [13]. With prolonged use in
postmarketing surveillance, it was noted that genotypic
resistance can be detected in 14% to 32% after 1 year of
lamivudine treatment and up to 70% after 5 years of
treatment [2••]. Virologic breakthrough in those with LAM-
resistant virus was usually followed by biochemical
breakthrough, with increase in serum alanine transaminase
(ALT), followed by acute exacerbations of liver disease and
even hepatic decompensation and death. Mutations in the
tyrosine-methionine-aspartate-aspartate (YMDD) motif oc-
cur frequently and confer genotypic resistance to LAM.
Lamivudine is now considered second-line therapy for
treatment naïve patients due to this resistance pattern. Rare
cases of neuropathy, pancreatitis, Fanconi syndrome, and
reversible myopathy have been reported in patients coin-
fected with HBV and HIV [13].
Adefovir
Adefovir dipivoxil is the orally bioavailable pro-drug of
adefovir (ADV), a nucleotide analogue that inhibits reverse
transcriptase and DNA polymerase and causes HBV chain
termination. ADV was developed as an antiretroviral for
HIV infection but due to nephrotoxicity at high doses, it
was not developed for this indication. For CHB, it was
approved at a dose of 10 mg daily in 2002. It was approved
for children 12 to 17 years of age in 2008. The two most
common side effects observed with adefovir therapy are
dose-dependent but reversible nephrotoxicity and antiviral
resistance [2••].
Grade 1 nephrotoxicity, defined as serum creatinine
≥0.5 mg/dL above baseline values, was not observed to be
an issue in the registration trials for ADV. Postmarketing
surveillance revealed a different picture, with 7% of
patients in a cohort of 29 patients coinfected with HIV
and LAM-resistant HBV demonstrating grade 1 nephrotox-
icity [14]. In a cohort of 185 patients with chronic hepatitis
B e antigen (HBeAg)-negative hepatitis B treated with






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































86 Curr Hepatitis Rep (2010) 9:75–90ADV for 5 years, grade 1 nephrotoxicity was seen in 3% of
patients with compensated liver disease [15]. In another
study, 6% on the transplant waiting list, and 47% of those
who underwent liver transplant during the study experienced
grade 1 nephrotoxicity [16]. Patients in the latter two groups
may have had alternate explanations for renal dysfunction
such as use of other nephrotoxic medications, hepatorenal
syndrome, or may have had a magnified effect of ADV due
to advanced liver disease.
A retrospective matched cohort study carried out in a
community setting by university investigators revealed that
over 100 patient years, ADV is an independent predictor for
significant deterioration of renal function, particularly with
older patients, baseline renal insufficiency, and/or diabetes
mellitus. In this study, incidence density for renal dysfunction
was defined by treatment termination and/or development of
eGFR ≤50 mL/minute, with 5 cases/100 patient years in the
ADV treatment group compared to 1.36 cases/100 patient
yearsintheunexposedgroup.Arelativeriskoftheexposedto
unexposed was 3.68with 95% confidence intervals of1.1 and
19.3. The authors stated that this may be a more realistic
picture of the renal dysfunction in the community as opposed
to a clinical trial [17]. Other studies have detected no change
in serum creatinine at a dose of 10 mg daily, including two
double-blind, placebo-controlled trials to investigate the
safety and tolerability of two dosing regimens for ADV,
10 mg daily and 30 mg daily. At the higher dose, patients
had an increase of 0.2 mg/dL in creatinine when treated for
more than 6 months [18].
The mechanism of nephrotoxicity with ADV is not
elucidated; however, there is likely proximal tubular injury
and a Fanconi-like renal tubular acidosis or alterations in
multidrug resistance protein 4 expression in renal tubular
epithelium. Dose reductions or increased dosing intervals in
those with renal insufficiency and monitoring of renal
function every 3 months for those with comorbidities that
predispose to renal insufficiency or in patients on the drug
for more than 1 year are recommended. Clinically,
nephrotoxicity will manifest as slight increases in serum
creatinine and decreases in serum phosphate levels occurring
4 to 12 months after starting ADV.
Resistance is a major concern emerging with use of ADV.
ADVresistancemay bemorefrequentinpatients who already
haveLAMresistance.Inanopen-labeltrialtostudymutations
in LAM resistant patients, 18% of the LAM-resistant patients
developed ADV resistant mutations, while none of the
treatment naïve patients developed mutations to ADV [19].
In a long term safety and efficacy study following patients
for 5 years on treatment, ALT flares were seen in 15 of 65
patients. These patients had ADV mutations [20]. Rare
serious adverse events include nasopharyngeal cancer,
spontaneous abortion, fracture, and bronchial pneumonia
[21]; however, it is not certain that these are attributable to
ADV. Further long term follow-up in patients to determine
adverse events associated with adefovir is needed.
Entecavir
Entecavir (ETV) is a nucleoside analogue of 2′deoxygua-
nosine and inhibits HBV replication at three different steps:
priming of HBV DNA polymerase, reverse transcription of
the negative-strand HBV DNA, and synthesis of the
positive-strand HBV DNA [2]. It was approved in 2005 at
a dose of 0.5 mg/d for treatment-naïve CHB patients and
1.0 mg/d for LAM-resistant patients. In animal studies,
there has been a higher incidence of solid tumors; long-term
human studies are underway.
Resistance is rare with entecavir in nucleoside treatment
naïve patients and when it does occur, it tends to happen in
those patients who already have LAM resistance. In a
double-blind, placebo-controlled study comparing the effi-
cacy of entecavir, 0.5 mg once daily, and lamivudine,
100 mg once daily, in HBeAg-positive CHB, there was no
virologic breakthrough due to entecavir resistance at
96 weeks. In lamivudine refractory patients, genotypic
resistance to entecavir was 51% [22, 23]. In 5 years of
follow-up of nucleoside-naïve patients from six phase 2 and
3 clinical studies of safety and efficacy of ETV, the
cumulative probability of genotypic entecavir resistance
(ETVr) and genotypic ETVr associated with virologic
breakthrough was 1.2% and 0.8%, respectively. In LAM-
refractory patients, the 5-year cumulative probability of
genotypic ETVr and genotypic ETVr associated with
breakthrough was 51% and 43%, respectively. Only four
patients who achieved less than 300 copies/mL HBV DNA
subsequently developed ETVr [24]. The 6-year resistance
data for entecavir reveal a cumulative probability of
genotypic resistance of 1.2% in nucleoside-naïve patients
and 57% in LAM-resistant patients. A total of 74 of 187
LAM-refractory patients (40%) achieved HBV DNA less
than 300 c/mL while on treatment with entecavir and of
those 74 patients, only 5 (7%) developed genotypic
resistance. The 6-year resistance data support the conclusion
thatETVhasahighgeneticbarriertoresistanceinnucleoside-
naïve patients. Even in the lamivudine-refractory patients,
favorable prognostic subgroups can be identified by response
to treatment with entecavir [25].
ETV is generally well tolerated even in patients with
advanced fibrosis and cirrhosis. In a post-hoc analysis of
three prospective, randomized, multicenter, double-blind
trials, patients with CHB and advanced hepatic fibrosis or
cirrhosis were randomly assigned to receive a minimum of
48 weeks of ETV or LAM. Nucleoside-naïve patients
receivedETV,0.5mgdaily.LAM-refractorypatientsreceived
entecavir, 1 mg daily, or continued LAM at 100 mg daily. The
frequency of on-treatment adverse events was comparable
Curr Hepatitis Rep (2010) 9:75–90 87among those with advanced liver fibrosis/cirrhosis and the
overall study population. No entecavir-treated patients dis-
continued therapy due to adverse events [26]. Entecavir has
been proven effective against CHB, but continued surveil-
lance is necessary to determine its long-term safety.
Telbivudine
Telbivudine is a potent L-nucleoside analogue approved for
the treatment of CHB in 2006 at a dose of 600 mg/d. It is
more potent than lamivudine in suppressing HBVreplication,
but it is associated with a high rate of viral resistance,
reflecting mutations cross-resistant with lamivudine, so
monotherapyislimited[2••]. The safety profile of telbivudine
looked similar to that of lamivudine in registration trials, but
at 2 years, significant adverse effects were noted [27, 28].
Creatine phosphokinase (CPK) elevations greater than 7
times the upper limit of normal were noted more frequently
in patients on telbivudine at 2 years as compared to patients
on lamivudine (12.9% with telbivudine compared to 4.1%
with lamivudine treated patients, P<0.001) [29]. Although
CPK levels were elevated to be between 191 IU/L and
900 IU/L, there was no correlation with severity of muscle
symptoms and absolute CPK elevations. On the other hand,
subjective myalgia was noted to be dose dependent [30].
Two patients developed myopathy that resolved with drug
discontinuation. Given these reports, it is recommended that
patients taking telbivudine undergo monitoring for musculo-
skeletal symptoms and CPK levels before commencing
therapy and then every 3 months during therapy.
Reports exist of moderately severe peripheral neuropathy
in 17% of patients treated with telbivudine and peginterferon
alfa-2a [31]. Accordingly, telbivudine is not recommended
for use in combination with peginterferon at this time.
Telbivudine in combination with adefovir and tenofovir is
currently being studied.
Tenofovir
Tenofovir disoproxil fumarate is a nucleotide analogue that
was approved for HIV infection as Viread (tenofovir alone)
or Truvada (tenofovir plus emtricitabine as a single pill)
(both, Gilead Sciences, Foster City, CA). It was approved
for CHB at a dose of 300 mg/d in 2008. It is structurally
similar to adefovir, but is less nephrotoxic, so higher doses
can be used, conferring better antiviral activity in clinical
studies [2••, 32, 33]. Tenofovir is currently recommended
as part of the nucleos[t]ide reverse transcriptase inhibitor
(NRTI) backbone in combination with a non-nucleoside
reverse transcriptase inhibitor (NNRTI) or protease inhibitor
asfirstlinehighlyactiveantiretroviraltherapy,whichmakesit
an excellent choice for therapy in coinfected individuals [34].
To date, neither phenotypic nor genotypic resistance to CHB
has been identified with tenofovir. It is effective against
lamivudine-resistant strains of CHB.
A 4% rate of nephrotoxicity is reported in HIV patients
taking tenofovir, but most were able to continue tenofovir at
reduced doses. Accordingly, it is recommended that serum
creatinine, phosphate levels, and urinalysis be monitored
every 3 months in patients taking tenofovir, because the
nephrotoxicity from this drug is thought to be reversible
with dose reduction or discontinuation. Decreased bone
density and osteomalacia have also been described in HIV
patients taking tenofovir. Bone density measurements and
calcium and vitamin D supplementation are recommended in
patients taking tenofovir for HIV. The experience with
tenofovir in CHB is still in its early stages, and long-term
data regarding nephrotoxicity, decreased bone density, and
osteomalacia in patients with CHB has not been determined.
Conclusions
The five approved nucleoside/nucleotide drugs for CHB
carry much promise for the treatment of this disease. The
side effects associated with these medications are clinically
significant, and close monitoring of patients while on
therapy is indicated. Future studies to address the long-
term safety profile of these nucleoside/nucleotide analogues
given for CHB are needed or currently underway. These
include studies assessing nephrotoxicity, myopathy, mito-
chondrial toxicity, bone mineral density, and drug resis-
tance. Additionally, further studies are needed to assess the
safety of nucleoside/nucleotide analogues in special patient
populations including pregnant women, children, the
elderly, and patients with decompensated liver disease.
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